Novo Nordisk Annual Report 2021
Contents Introducing Novo Nordisk Strategic Aspirations Key risks
Management
Consolidated statements
Additional information.
Novo Nordisk Annual Report 2021 29
O+
Patent status for
marketed products
The patent expiry dates for the products are shown in the
table on the right. The dates provided are for expiry in
the US, China, Japan and Europe of patents on the active
ingredient, unless otherwise indicated, and include actual
and estimated extensions of patent term, when applicable.
For several products, in addition to the active ingredient
patent, Novo Nordisk holds other patents on manufacturing
processes, formulations or uses that may be relevant for
exclusivity beyond the expiration of the active ingredient
patent. Furthermore, regulatory data protection and/or
orphan exclusivity may apply.
Key marketed products in main markets (active ingredients)
Diabetes:
Human insulin and Modern insulins'
Novo Norm (PrandinⓇ)
VictozaⓇ9
Tresiba®
RyzodegⓇ
XultophyⓇ
FiaspⓇ
OzempicⓇ
RybelsusⓇ
Obesity:
SaxendaⓇ
WegovyⓇ
Biopharm:
Norditropin® (SimpleXxⓇ)
Sogroya®
NovoSevenⓇ
NovoEight®
NovoThirteenⓇ (TRETTEN®)
Refixia (REBINYN®)
Esperoct
Vagifem 10 mcg
US
China
Japan
Europe³
Expired
Expired
Expired
Expired
Expired
Expired
Expired
Expired
2023
Expired
2022
2023
2029
2024
2027
2028
2029
2024
2024²
2028
2029
2024
20242
2028
20303
2030³
20303
20303
2032
2026
2031
2031
20324
20264
20314
20314
2023
2032
Expired
2026
Expired
2023
2031
2031
Expired
2034
Expired
No patent
Expired
2028
Expired
2031
Expired5
Expired
2036
Expired
No patent
Expired
No patent
No patent
2036
Expired
No patent
No patent
No patent
2022
2027
2027
2032
2029
2034
2034
20226,7
No patent
Expired
Expired
1. Modern insulins are NovoRapid® (NovoLogⓇ), NovoMix® 30 (NovoLog® Mix 70/30) and Levemir® 2. Patent term extension until 2027 may apply 3. Formulation patent; active ingredient
patent has expired 4. Tablet formulation and once-daily treatment regimen are protected by additional patents expiring in 2031-2034 5. Room temperature-stable formulation patent
until 2023 in China, Japan and Germany and until 2025 in the US 6. Patent covers low-dose treatment regimen 7. Licensed to several generic manufacturers from October 2016
8. Patent status varies from country to country. The figures in the table are based on Germany 9. We have granted and pending patents covering the VictozaⓇ formulation.
These patents generally expire in November 2024, except for the US where the formulation patent expires in February 2026View entire presentation